Click here for slides on this topic


L-cell

A type of cell foundin the gut that is responsible for the secretion of glucagon-like peptide (GLP)-1.
The following content matched the glossary term: L-cell

β-cell function preservation after 3.5 years of intensive diabetes therapy

Top

Harrison LB, Adams Huet B, Raskin P, Lingvay I. Beta cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412. To assess beta-cell function preservation after 3.5 years of intensive therapy with insulin plus metformin (INS group) versus triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone.

NDEI.org Expert Commentary on ORIGIN Glargine Trial Silvio Inzucchi, MD

Top

Expert commentary on ORIGIN glargine diabetes trial Silvio Inzucchi, MD.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 8, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 8, 2012

Diabetes and hypoglycemia, clinical management of diabetes, obesity treatment, diabetes in long-term care, and more. 

ADA/European Association for the Study of Diabetes (EASD) Position Statement on Hyperglycemia Management in Type 2 Diabetes

Top

Joint position statement from ADA/EASD with clinical practice recommendations for managing hyperglycemia in type 2 diabetes

NDEI.org Expert Commentary Diabetes Monotherapy DURATION -4 Vivian Fonseca

Top

Expert commentary on diabetes monotherapy in DURATION-4 from Vivian Fonseca, MD

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes

Top

Defronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP 4 inhibitor alogliptin combined with pioglitazone, in metformin treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012 Mar 14. Epub ahead of print. Optimal management of type 2 diabetes remains an elusive goal. Combination therapy addressing the core defects of impaired insulin secretion and insulin resistance shows promise in maintaining glycemic control.

Clinical Insights in Diabetes Newsletter Archive

Top

Clinical Insights® in Diabetes Newsletter Archive

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: L-cell Slides Found: 77
Sulfonylureas: Prescribing Considerations
Risk Factors for Conversion to Diabetes in Mexican Americans
Treating Insulin Resistance Reduces Incidence of Type 2 Diabetes
Treating Insulin Resistance Preserves b-Cell Function
Type 2 Diabetes Prevention Studies
Effect of Pioglitazone on B-Cell Function: HOMA bCF
PPARg Ligand May Prevent Loss of B-Cell Mass
PPARs and Peroxisomes (animated)
PPARa and HDL Metabolism (animated)
PPARg Exerts Antiatherogenic Effects via Multiple Vascular Targets (animated)
Comparison of Diabetes Rates Across PIPOD and TRIPOD
Glucagon-Like Peptide-1
Effect of GLP-1 on the Beta-Cell
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
GLP-1 and First-Phase Insulin Secretion
Exenatide: Effect on the Beta-Cell
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
Regulation of Insulin Secretion
Beta-Cell Adaptation to Insulin Resistance: Longitudinal Data in Normal Women
Plasticity of Islets: Experimental Increase in Beta-Cell Mass in Response to IR
Neogenesis May Contribute to Increased Islet Mass in Obese Humans
Hypothetical Relationships Determine Categories of Glucose Tolerance
Type 2 Diabetes: Pathogenesis in a Nutshell
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
Type 2 Diabetes: Pathogenesis in a Nutshell (cont.)
Decreased beta-Cell Function in Groups With Diabetes and at High Risk
Short-term beta-Cell Adaptation: Response to Pregnancy
Declining beta-Cell Function: Best Correlation of Progression
Loss of beta-Cell Function in People Who Develop Type 2 Diabetes: Longitudinal Data
Changing Glucose: Different Rates at Different Clinical Stages
UKPDS: Progressive Deterioration in Glycemic Control Over Time
UKPDS: Progressive Deterioration in beta-Cell Function Over Time
Acute Insulin Response to Glucose
Acute Insulin Response to Arginine
Beta-Cell Mass in Normal Patients and Patients With Diabetes: Autopsy Study
Altered beta-Cell Mass and Function in Islets From Subjects With Type 2 Diabetes
Role of Islet Amyloid in beta-Cell Dysfunction
Tools to Assess beta-Cell Health and Function
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
ADOPT: Achievement of A1C Levels <7%
Vildagliptin + Pioglitazone Increases Beta-Cell Insulin Secretory Rate
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Vildagliptin vs Metformin: A1C
Whitehall II: Design
Whitehall II: Fasting Glucose From Baseline to 13 Years
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
Whitehall II: HOMA Insulin Sensitivity Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: HOMA b-Cell Function Trajectory Before Diagnosis of Diabetes or End of Follow-Up
Whitehall II: Conclusion
Whitehall II: 2-Hour Postload Glucose From Baseline to 13 Years
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Reduction in Truncal Fat with Gastric Bypass Vs Sleeve Gastrectomy
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
STAMPEDE Metabolic Substudy: Design
Liraglutide 12-Week Treatment: Effect on Glycemic Control
Liraglutide Improves ß-Cell Function and Insulin Secretion During Hyperglycemia in Patients With Type 2 Diabetes
Liraglutide Enhances Glucose-Dependent Insulin Secretion
GLP-1 Receptor Agonists Type 2 Diabetes Treatment | NDEI
Type 1 Diabetes Classification & Diagnosis
ADA Type 1 Diabetes Guidelines Diagnosis Clues Slide | NDEI
Beta-Cell Replacement ADA Type 1 Diabetes Guidelines | NDEI